Alta Capital Management’s AbbVie ABBV Stock Holding History

Alta Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$317K	Sell	1,261 -398	-24%	-$85.6K	0.02%	89
2026 Q1	$361K	Buy	1,659 +131	+9%	+$29.1K	0.03%	79
2025 Q4	$349K	Sell	1,528 -1,723	-53%	-$393K	0.02%	76
2025 Q3	$753K	Buy	3,251 +16	+0.5%	+$3.26K	0.04%	72
2025 Q2	$600K	Hold	3,235	–	–	0.03%	70
2025 Q1	$678K	Hold	3,235	–	–	0.04%	69
2024 Q4	$575K	Hold	3,235	–	–	0.03%	72
2024 Q3	$639K	Hold	3,235	–	–	0.04%	68
2024 Q2	$555K	Sell	3,235 -125	-4%	-$20.7K	0.03%	72
2024 Q1	$612K	Sell	3,360 -250	-7%	-$43.1K	0.04%	71
2023 Q4	$559K	Hold	3,610	–	–	0.04%	71
2023 Q3	$538K	Hold	3,610	–	–	0.04%	68
2023 Q2	$486K	Hold	3,610	–	–	0.03%	72
2023 Q1	$575K	Sell	3,610 -235	-6%	-$35.9K	0.04%	70
2022 Q4	$621K	Sell	3,845 -125	-3%	-$19.2K	0.05%	65
2022 Q3	$532K	Hold	3,970	–	–	0.04%	65
2022 Q2	$608K	Sell	3,970 -200	-5%	-$30.6K	0.04%	68
2022 Q1	$675K	Buy	4,170 +235	+6%	+$34.1K	0.04%	68
2021 Q4	$532K	Sell	3,935 -240	-6%	-$28.4K	0.03%	71
2021 Q3	$450K	Sell	4,175 -4,175	-50%	-$477K	0.03%	73
2021 Q2	$940K	Hold	8,350	–	–	0.03%	75
2021 Q1	$903K	Buy	8,350 +4,175	+100%	+$447K	0.03%	72
2020 Q4	$447K	Sell	4,175 -4,875	-54%	-$468K	0.03%	70
2020 Q3	$792K	Hold	9,050	–	–	0.03%	69
2020 Q2	$888K	Hold	9,050	–	–	0.03%	69
2020 Q1	$689K	Buy	9,050 +4,488	+98%	+$382K	0.03%	72
2019 Q4	$403K	Hold	4,562	–	–	0.03%	70
2019 Q3	$345K	Sell	4,562 -190	-4%	-$13K	0.02%	74
2019 Q2	$345K	Hold	4,752	–	–	0.02%	74
2019 Q1	$382K	Sell	4,752 -18,637	-80%	-$1.52M	0.02%	70
2018 Q4	$2.16M	Buy	23,389 +1,195	+5%	+$105K	0.14%	46
2018 Q3	$2.1M	Buy	22,194 +699	+3%	+$66.3K	0.12%	44
2018 Q2	$1.99M	Buy	21,495 +210	+1%	+$20.5K	0.12%	44
2018 Q1	$2.01M	Sell	21,285 -263	-1%	-$28.9K	0.13%	42
2017 Q4	$2.08M	Sell	21,548 -5,846	-21%	-$551K	0.13%	42
2017 Q3	$2.43M	Buy	27,394 +29	+0.1%	+$2.21K	0.16%	42
2017 Q2	$1.98M	Buy	27,365 +411	+2%	+$27.6K	0.13%	42
2017 Q1	$1.76M	Buy	26,954 +306	+1%	+$19.2K	0.12%	47
2016 Q4	$1.67M	Sell	26,648 -126	-0.5%	-$7.69K	0.12%	51
2016 Q3	$1.69M	Buy	26,774 +1,208	+5%	+$78.2K	0.11%	49
2016 Q2	$1.58M	Buy	25,566 +643	+3%	+$39.2K	0.1%	54
2016 Q1	$1.42M	Sell	24,923 -457	-2%	-$25.5K	0.09%	53
2015 Q4	$1.5M	Sell	25,380 -714	-3%	-$41.1K	0.12%	53
2015 Q3	$1.42M	Sell	26,094 -2,063	-7%	-$134K	0.12%	52
2015 Q2	$1.89M	Sell	28,157 -2,781	-9%	-$182K	0.16%	51
2015 Q1	$1.81M	Buy	30,938 +1,616	+6%	+$97.6K	0.15%	52
2014 Q4	$1.92M	Sell	29,322 -303	-1%	-$19.1K	0.16%	48
2014 Q3	$1.71M	Buy	29,625 +526	+2%	+$29.2K	0.16%	49
2014 Q2	$1.64M	Buy	29,099 +792	+3%	+$41.5K	0.15%	52
2014 Q1	$1.46M	Sell	28,307 -201	-0.7%	-$10.2K	0.14%	52
2013 Q4	$1.5M	Buy	28,508 +4,222	+17%	+$208K	0.15%	51
2013 Q3	$1.09M	Buy	24,286 +2,263	+10%	+$100K	0.13%	51
2013 Q2	$910K	Buy	+22,023	New	+$963K	0.12%	54

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Alta Capital Management's ABBV Position: Q2 2026 in Review

Alta Capital Management reduced its AbbVie (ABBV) stake by 24% in Q2 2026, selling an estimated $85.6K and leaving 1,261 shares worth $317K. The position accounts for 0.02% of the portfolio, ranked #89.

Alta Capital Management first reported a position in ABBV in Q2 2013 and has held it in 53 quarters since. The position peaked at $2.43M in Q3 2017. 4,193 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Alta Capital Management held 1,261 shares of AbbVie worth $317K as of Q2 2026.
Alta Capital Management sold 398 AbbVie shares in Q2 2026, an estimated $85.6K.
AbbVie made up 0.02% of Alta Capital Management's portfolio in Q2 2026, its #89 holding.
Alta Capital Management first reported a position in AbbVie in Q2 2013 and has held it in 53 quarters since.
Alta Capital Management's AbbVie position peaked at $2.43M in Q3 2017.
4,193 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Alta Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.